Spinal Cord Stimulation Global Market Report 2024

The spinal cord stimulation market size has grown strongly in recent years. It will grow from $2.85 billion in 2023 to $3.12 billion in 2024 at a compound annual growth rate (CAGR) of 9.4%. The growth observed during the historical period can be attributed to factors such as an aging population, the increasing prevalence of chronic pain, rising awareness about spinal cord stimulation, and a growing demand for non-invasive pain management techniques.

The spinal cord stimulation market size is expected to see strong growth in the next few years. It will grow to $4.31 billion in 2028 at a compound annual growth rate (CAGR) of 8.3%. The anticipated growth in the forecast period can be attributed to the development of innovative stimulation therapies, the expansion of indications for spinal cord stimulation, a rising demand for minimally invasive procedures, increased investment in research and development, and favorable reimbursement policies. Major trends expected in the forecast period include the integration of artificial intelligence in spinal cord stimulation devices, the emergence of non-paresthesia-based stimulation, a focus on expanding market presence in emerging economies, the adoption of rechargeable stimulators, and an emphasis on patient-centric approaches in product development.

The expected rise in the prevalence of spinal cord injuries is anticipated to drive the growth of the spinal cord stimulation market in the future. Spinal cord injuries encompass any damage to the spinal cord or nerves within the spinal canal, often resulting from traumatic incidents or domestic accidents. The treatment for spinal cord injuries involves spinal cord stimulation, a process that delivers low-voltage electricity to the spinal cord to alleviate pain. As of May 2022, the National Library of Medicine reported that spinal cord injuries affected between 250,000 and 500,000 individuals globally each year. In the United States alone, approximately 17,000 new spinal cord injuries are reported annually, with an estimated 282,000 Americans considered survivors of spinal cord injuries. Consequently, the growing prevalence of spinal cord injuries is serving as a catalyst for the expansion of the spinal cord stimulation market.

The increasing demographic of the elderly population is expected to contribute to the growth of the spinal cord stimulation market. The geriatric population, aged 65 and older, experiences distinctive healthcare and social needs associated with the aging process. The expanding geriatric population represents a significant market opportunity for spinal cord stimulation, as age-related ailments and chronic pain become more prevalent. In May 2021, a report by The Administration for Community Living (ACL) indicated a 36% increase in the population aged 65 and older from 39.6 million in 2009 to 54.1 million in 2019. Projections suggest that this demographic will reach 94.7 million by 2060, with estimates indicating a figure surpassing 80.8 million by 2040. This demographic shift, more than doubling from 2000, is expected to constitute 21.6% of the total population by 2040, compared to 16% in 2019. Hence, the expanding geriatric population is a driving force for the growth of the spinal cord stimulation market.

Technological innovations are a prominent trend gaining traction in the spinal cord stimulation market, with major companies focusing on advanced solutions to maintain their market positions. In December 2022, Abbott Laboratories, a US-based medical device company, introduced the Eterna spinal cord stimulation system, the smallest implantable, rechargeable spinal cord stimulator for chronic pain management currently available. Utilizing Abbott's low-dose BurstDR stimulation, the Eterna SCS has demonstrated a 23% greater relief of pain compared to conventional waveform technology methods, providing a technologically advanced solution for chronic pain treatment.

Major players in the spinal cord stimulation market are concentrating on developing innovative products, such as the Spinal Cord Stimulation System, representing a significant advancement in therapy for spinal cord stimulation. The system involves the implantation of electrodes along the spinal cord to alleviate chronic pain. In March 2023, Nevro, a US-based medical device company specializing in chronic pain treatment, launched the Revolutionary HFX iQ Spinal Cord Stimulation System. Distinguished by its use of artificial intelligence, the system offers personalized pain relief through real-time adjustments based on extensive clinical data. Featuring the HFX algorithm and comprehensive pain management, this system not only represents a significant advancement in spinal cord stimulation therapy but also contributes to the market by offering innovative, data-backed, and AI-powered solutions for individuals with chronic pain.

In November 2023, Nevro, a US-based medical device company for chronic pain, completed the acquisition of VYRSA Technologies for an upfront payment of $40 million and an additional $35 million in milestone payments. This acquisition is notable in the spinal cord stimulation market, diversifying Nevro's product offering, expanding its portfolio and market reach, and addressing unmet medical needs in chronic pain treatment. VYRSA Technologies is a US-based medical technology company with a focus on sacroiliac joint fusion.

Major companies operating in the spinal cord stimulation market report are NeuroPace Inc., Abbott Laboratories, Medtronic PLC, Stryker Corporation, Boston Scientific Corp., LivaNova PLC, Globus Medical Inc., ZimVie Inc., Avanos Medical Inc. , Inspire Medical Systems Inc., Nevro Corp., Axonics Modulation Technologies Inc., SPR Therapeutics Inc., BlueWind Medical, Bioness Inc., Saluda Medical Pty. Ltd., Soterix Medical Inc., Synapse Biomedical Inc., NeuroMetrix Inc., NDI Medical LLC, Neuros Medical Inc., Cirtec Medical Corp., Mainstay Medical International PLC, Gimer Medical, NeuroSigma Inc.

North America was the largest region in the spinal cord stimulation market in 2023. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the spinal cord stimulation market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the spinal cord stimulation market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The primary types of spinal cord stimulation products are rechargeable and non-rechargeable. Rechargeable devices are those capable of being replenished with electricity. Rechargeable spinal cord stimulation is applied to address persistent neuropathic pain that persists after unsuccessful back surgery. Its applications extend to various conditions, including failed back surgery syndrome (FBSS), degenerative disc disease (DDD), complex regional pain syndrome (CRPS), arachnoiditis, among others. These products find use in different medical settings, including hospitals, ambulatory surgery centers, and specialty clinics.

The spinal cord stimulation market research report is one of a series of new reports that provides spinal cord stimulation market statistics, including spinal cord stimulation industry global market size, regional shares, competitors with a spinal cord stimulation market share, detailed spinal cord stimulation market segments, market trends and opportunities, and any further data you may need to thrive in the spinal cord stimulation industry. This spinal cord stimulation market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The spinal cord stimulation market consists of sales of neurostimulators, leads, extensions, and handheld controllers. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.